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Abstract 
The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are 
insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus 
(T2DM). Thiazolidinediones significantly improve glycaemic control in diabetics by 
reduced fasting glucose, insulin and glycated haemoglobin and they delay the 
progression of insulin resistance/impaired glucose tolerance into T2DM. It is well 
recognized that adequate glycaemic control and subsequent amelioration of 
hyperinsulinaemia and hyperglycaemia can delay the onset of vascular 
complications. TZDs, however, also have a number of anti-atherogenic effects 
independent of their influences on glucose and insulin metabolism. They improve 
lipid profiles, lower blood pressure, have anti-inflammatory properties, improve 
endothelial function and increase large artery compliance in patients with type 2 
diabetes mellitus.  When compared to rosiglitazone, pioglitazone has more 
favourable effects on the lipid profiles of patients with T2DM. The disease 
preventive actions of TZDs may be the result of their agonistic effects on 
peroxisome proliferator-activated receptors (PPARs), ligand-activated transcription 
factors that regulate the expression of numerous genes and affect metabolism and 
vascular parameters.  
 
Thiazolidinediones, provide an effective treatment for populations with insulin 
resistance which is at high risk of developing cardiovascular disease. This paper 
discusses the differences between ROS and PIO and explores their anti-
atherogenic effects with particular focus on post-menopausal women with type 2 
diabetes mellitus. 
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Introduction 
Diabetes Mellitus is a metabolic disorder characterised by increased blood glucose 
levels and premature development of micro and macrovascular disease. In Type 2 
diabetes (T2DM) cardiovascular disease (CVD) is the most significant cause of 
decreased quality of life and increased mortality and morbidity. Approximately 80 
per cent of all deaths in patients with T2DM are due to cardiovascular disease [1]. 
Patients with T2DM have a two to four-fold increased risk of both coronary heart 
disease and stroke compared with those without diabetes. T2DM is also 
associated with hyperinsulinaemia, insulin resistance and other metabolic 
abnormalities, including hypertension, obesity and dyslipidaemia. Insulin 
resistance is an important component of the metabolic syndrome, which includes a 
cluster of factors such as obesity, hypertension and dyslipidaemia and which 
contributes to the increased incidence of cardiovascular risk [2]. It is postulated 
that insulin resistance and hyperinsulinaemia are independent risk factors for 
coronary artery disease, with a level of increased risk similar to that of 
hyperlipidaemia [3]. 
 
Increasing body weight, age and menopause are the main catalysts for alterations 
in glucose and insulin metabolism, which, if left untreated, may lead to the 
development of insulin resistance or T2DM.   Decreased oestrogen levels are 
associated with increased circulating glucose concentrations, reduced insulin 
responses to glucose and hyperinsulinaemia [4], possibly via alterations in insulin 
receptor concentrations. Reduced participation in physical activity, increased 
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adiposity and altered fat distribution, which occur at the time of menopause, may 
well be important factors that compound the effects of reduced oestrogen levels on 
altered glucose and insulin metabolism.  
 
Diabetes and oestrogen deficiency at the time of menopause, are associated with 
increased stiffness of large arteries, which may contribute to the pathogenesis of 
CVD and subsequent morbidity and mortality in women. Post-menopausal women 
experience a sharp increase in the rate of cardiovascular disease [5], although 
whether this is independently related to menopause itself remains controversial.  
 
Diabetes, aging and oestrogen reduction are associated with impaired endothelial 
function and altered arterial mechanical properties. Endothelial dysfunction plays 
an important role in the pathogenesis of vascular disease [6]. Similarly, arterial 
stiffening is associated with systolic hypertension [7], reduced coronary perfusion 
[8] and coronary artery disease [9]. Alterations in vascular structure and function 
are a feature of the micro– and macrovascular complications of diabetes. 
Assessment of the effects of drugs on the biological properties of vascular tissue 
has proved useful for identifying effective strategies for cardiovascular risk 
reduction.  
 
This article will review some of the evidence regarding the biological and 
antiatherogenic effects of TZD.  In view of the importance of the increased risk of 
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CVD after menopause particular reference will be made to post-menopausal 
women with type 2 diabetes mellitus. 
 
Thiazolidinediones  
Thiazolidinediones (often referred to colloquially as ‘glitazones’) are oral 
antidiabetic agents widely used to treat patients with T2DM that act primarily as 
insulin sensitizers, improving glucose control and decreasing insulin resistance. 
Rosiglitazone and pioglitazone are two compounds in this class of insulin 
sensitizing drugs presently approved for use in many countries as monotherapy or 
in combination with metformin, sulfonylureas or insulin. It is well established that 
they enhance peripheral glucose uptake and improve insulin sensitivity in patients 
with T2DM [10] and prevent progression to T2DM in patients with impaired glucose 
tolerance and insulin resistance [11].  
 
Thiazolidinediones have a major effect on adipose tissue and skeletal muscle and 
are also active in liver [12]. They are more effective in increasing insulin sensitivity 
than the biguanide metformin [13], which acts primarily on the liver and to a lesser 
extent on the skeletal muscle by a still unknown mechanism [14]. 
 
Thiazolidinediones exhibit a number of potential anti-atherogenic actions in Type 2 
diabetic patients, including: improvement in lipoprotein profiles via the reduction of 
oxidized LDL [15], circulating triglyceride levels [16,17], improvements in vascular 
reactivity  via suppression of endothelin-1 levels and  inhibition of extracellular 
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calcium uptake by vascular smooth muscle cells (VSMC), apparently through 
inhibition of L-type calcium channels [18]. TZD also inhibit vascular smooth muscle 
cell proliferation and migration [19]. They have also been shown to improve 
endothelial function, reduce inflammation and decrease plasma FFA and blood 
pressure [10, 20, 21]. 
 
Further details regarding the history of this class of medication, their chemical 
structure and their relationship to other antidiabetic agents can be found in recent 
reviews by Yki Jarvinen [22] and Natali and Ferrannini [23]. 
 
Modes of Action of Thiazolidinediones 
Thiazolidinediones act on adipose tissue to decrease plasma free fatty acids 
(FFAs) and secretion of tumour necrosis factor-α (TNF- α) and resistin, often 
increased with obesity and diabetes, therefore improving insulin action in muscle, 
adipose tissue and liver. They are believed to increase insulin sensitivity by 
activating highly selective and potent nuclear receptors, the peroxisome 
proliferator-activated receptor-gamma (PPARγ), thereby directly regulating gene 
expression as a result of which peripheral glucose uptake is increased and hepatic 
glucose production is diminished [24]. The PPARs are a family of nuclear 
receptors comprised of three different subtypes, α, β and γ.  PPARs receptors are 
found in target tissues for insulin action such as skeletal muscle, adipose tissue, 
and liver and it appears that they are important regulators for insulin action, lipid 
homeostasis and adipocyte differentiation. Once activated, the receptors alter 
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transcription of numerous target genes by interacting with specific DNA response 
elements located upstream of responsive genes (Fig 1).   
 
 
 
Fig 1. Activation of the PPAR receptors leading to the transcription of the 
responsive gene. (From: David Bishop-Bailey, Br J Pharmacol 2000, 129:823-834) 
Legend: PPAR= peroxisome proliferator-activated receptor, RA= retinoic acid, PPRE= 
peroxisome proliferators response element, RXR=retenoid X receptor     
 
PPARγ regulation of gene expression occurs primarily in adipose tissue where, 
among other things, under anaerobic conditions it promotes lipogenesis [21]. The  
effects of PPARγ activation on glucose, lipid and insulin metabolism provide 
therapeutic potential for exogenous ligands of this receptor to reduce altered 
glucose and insulin metabolism and redress the metabolic abnormalities of T2DM 
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[15]. Further discussion regarding differential action of TZDs on PPAR can be 
found in Yki-Jarvinen’s review paper [22[. 
 
 
Anti-atherogenic Actions of Thiazolidinediones:  Effects on Glycaemic 
Control and Cardiovascular Markers 
The ability of thiazolidinediones to enhance peripheral glucose uptake and improve 
insulin sensitivity have been demonstrated in clinical studies of patients with 
T2DM. When used both as monotherapy and in combination therapy their effects 
appear to be similar in patients with T2DM and in individuals with impaired glucose 
tolerance and insulin resistance. Prospective and retrospective studies have 
shown that both ROS and PIO improve blood glucose and glycosylated 
haemoglobin levels (HbA1c) [24-26] and lead to similar degrees of weight gain [27, 
28]. In addition to improving glycaemic control TZDs are associated with 
favourable effects on other cardiovascular risk parameters such as blood pressure, 
fibrinogen, cell wall inflammatory markers [20] and beta cell function [29].    
 
Other properties of thiazolidinediones that may contribute to their blood pressure 
lowering actions include inhibitory effects on vascular smooth muscle cell (VSMC) 
migration and proliferation, mentioned above. In this manner, thiazolidinediones 
appear to inhibit a key step in the development of atherosclerotic plaque, which 
typically involves VSMC migration from media to intima [30, 31], proliferation of 
VSMCs and subsequent increased production of extracellular matrix proteins [32]. 
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VSMC migration and proliferation are thought to represent essential processes in 
the development of vascular remodelling, atherosclerosis and diabetic organ 
complications (Fig 2). It is noted that the evidence for apparently beneficial effects 
of TZD on these processes derives from in vitro and animal studies and that their 
clinical implications for humans remain to be fully elucidated.  
 
 
Fig2. PPAR regulate vascular and inflammatory cell functions. (From: 
David Bishop-Bailey, Br J Pharmacol 2000, 129: 823-834) 
Legend: COX2=cyclo-oxygenase expression, TNF-α=tumour necrotic factor- α, 
CD36=OxLDL scavenger receptor , Gel-B=gelatinase-B, PAI-1= plasminogen activator 
inhibitor-1, IL-6= interlukin-6 
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Effects on Lipid Metabolism 
Dyslipidaemia associated with diabetes is often associated with an increase in 
triglyceride levels, a decrease in HDL-C levels and mild elevation of LDL-C levels, 
while insulin resistance with or without hyperglycaemia is associated with 
qualitative changes in LDL cholesterol levels, which in turn are associated with a 
greater risk of cardiovascular disease and atherosclerosis [14]. There is also 
extensive evidence of deterioration in lipid profiles after menopause [5]. Both 
comparative and non-comparative studies of TZDs suggest that PIO and ROS 
have significantly different effects on plasma lipids independent of glycaemic 
control and other antihyperglycaemic therapy [26, 28].. Even in the absence of 
obvious hyperglycaemia, insulin resistance is associated with dyslipidaemia. 
Although plasma levels of LDL-C in patients with Type 2 diabetes might not differ 
greatly from those in non-diabetic patients, LDL-C particle sizes and 
concentrations differ. T2DM patients have smaller, dense particles rich in LDL- 
cholesterol which make the cholesterol more susceptible to oxidation and in turn 
may stimulate the inflammatory changes which promote atherosclerosis [15]. It is 
hypothesized that changes in the composition of LDL-C particles are associated 
with greater risk for atherosclerosis and cardiovascular complications and that the 
increased triglyceride levels in T2DM patients are partially responsible for the 
atherogenic changes in LDL-C profile [15]. 
 
Both ROS and PIO appear to substantially increase HDL cholesterol [22]. Overall, 
however, pioglitazone has been shown to have a more favourable effect on lipid 
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profiles in patients with T2DM, by also significantly reducing serum triglycerides, 
total cholesterol and LDL-C [16-17, 22, 26-27], Furthermore, pioglitazone improves 
LDL-C particle concentration and size, converting small, dense LDL-C particles 
into larger, less atherogenic lipoprotein particles [15]. These differences between 
the effects of ROS and PIO on lipids appear to be due to the different modes of 
action on PPAR receptors  PIO seems to act like a partial PPAR(α) agonist in vivo, 
while ROS seems to act like a pure PPAR(γ) agonist [33]. Increases in LDL-C 
have been noted with rosiglitazone [22], but not with PIO. The cause of this 
difference is unknown. Despite the fact that the two TZDs belong to the same 
broad pharmaceutical class, as the differences in the responses of lipid profiles 
show, they act through slightly different mechanisms, with different affinities for 
specific subtypes of the peroxisome proliferator-activated receptors (PPARs). It is 
thought that rosiglitazone interacts exclusively with PPARγ receptor, providing its 
insulin-sensitizing effects, while pioglitazone may activate both PPARα and 
PPARγ. The PPARα activation by pioglitazone may explain its different effect on 
TG levels [26].   
 
The hypertriglyceridaemia, hyperglycaemia and hyperinsulinaemia seen in patients 
with T2DM have been associated with increased levels of plasminogen activator 
inhibitor factor-1 (PAI-1), known to increase the predisposition towards coronary 
artery thrombosis. Reductions in PAI-1 have been noted in patients taking TZDs 
[34].   
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Although the evidence is suggestive, whether the differences in lipid profiles 
between the two TZDs lead to different cardiovascular outcomes remains 
uncertain. It is expected that clinical trials currently underway will provide further 
information about this important clinical issue. 
 
Effects on Endothelial Function 
Vascular endothelial cells play an important role in maintaining cardiovascular 
homeostasis in healthy individuals. In addition to providing a physical lining to the 
blood vessels, endothelial cells secrete various factors that influence vessel tone, 
platelet function, coagulation and fibrinolysis [35]. These include vasoconstrictive 
substances, such as thromboxane A2, endothelin-1, and vasodilating substances, 
such as prostaglandins (PGI2) and nitric oxide (NO). NO is a key factor in 
controlling vascular tone in large coronary and systemic arteries. Individuals with 
increased cardiovascular risk often have abnormalities of endothelial function, well 
before the onset of clinically symptomatic cardiovascular disease [19]. PGI2 and 
NO also inhibit platelet aggregation and reduced levels of these substances are 
often found in patients at high risk of atherosclerotic disease.  
 
In addition, insulin resistance is associated with increased cell adhesion and 
VSMC proliferation, which may contribute to increased cardiovascular risk. There 
is evidence to support the hypothesis that glucose has the ability to scavenge NO, 
thus contributing to endothelial dysfunction [36] and hyperglycaemia is recognised 
as an independent risk factor for the development of CVD [37].  Accumulation and 
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oxidation of plasma LDL-C in endothelial spaces in T2DM patients leads to the 
activation of endothelial cells and the synthesis of chemotactic molecules in the 
sub-endothelial space [19]. Long-term hyperglycaemia results in the accumulation 
of advanced glycation end products on collagen fibres, affecting arterial 
mechanical properties and reducing arterial elasticity [38].  
 
Impaired endothelial function also plays an important role in the development of 
hypertension [39]. A number of mechanisms for endothelial dysfunction have been 
demonstrated in various vascular beds of animal models and in humans with 
diabetes. These include reduced substrate availability [40], impaired signal 
transduction pathways [41], attenuated release, and increased destruction of 
endothelial derived relaxation factors (EDRF) [42], increased release of endothelial 
derived constricting factors [43], and a reduced sensitivity of vascular smooth 
muscle cells to EDRF [44]. It is well established that the hormonal changes 
associated with menopause also lead to development of endothelial dysfunction 
[6-9]. 
 
Thiazolidinediones have been shown to improve endothelial function [10, 22, 45-
46].  Enhanced glycaemic control itself is likely to be an important contributing 
factor, but  TZD treatment leads to stabilisation of endothelial cells [47], and in 
addition, results in direct anti-inflammatory actions on endothelial cells, probably 
mediated via PPARγ receptors [48]. Experiments in bovine endothelial cells in 
culture have shown inhibition of vasoconstriction due to endothelin-1, as a result of 
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diminished endothelin 1 mRNA expression and secretion [49],  
 
Thiazolidinediones have been shown to influence endothelium-dependent and 
endothelium-independent vascular tone in potentially beneficial ways. They inhibit 
extracellular calcium uptake by VSMC by blocking L-type calcium channels [18]. 
These actions may also contribute to the demonstrated effect of TZDs of reducing 
blood pressure and retarding the development of hypertension in T2D [50].  
Inhibitory effects on vascular smooth muscle cell proliferation and migration, 
previously mentioned, may also add to this antihypertensive effect [51]. 
 
Troglitazone, an older TZD, now withdrawn from sale because of hepatic toxicity, 
has also been shown to up-regulate cytokine-stimulated nitric oxide synthesis in 
VSMCs [52], an action which may inhibit the effects of numerous growth factors on 
VSMCs. Data concerning similar actions of ROS and PIO in clinical settings are 
lacking; if, however, these two drugs work in similar ways it this would have 
important implications for the possible prevention of the development and 
progression of atherosclerosis. 
 
In summary, TZDs appear to act in a manner that is potentially favourable with 
respect to cardiovascular risk through a number of separate pathways. Of crucial 
importance, however, is whether these actions translate into clinical endpoints, 
including a reduction in cardiovascular events or mortality from cardiovascular 
causes. These agents are not problem-free and the long term implications of 
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adverse effects associated with them - such as weight gain, peripheral and 
pulmonary oedema [53] and congestive heart failure [54] - remain to be clarified. 
(These issues are further discussed in the section ‘Adverse Effects of 
Thiazolidinediones’ below). 
  
Studies with sufficient power to test long term clinical outcomes, such as impact on 
mortality, cardiovascular events and other clinical indices of progression of 
complications of diabetes, are clearly needed. Such studies will contribute to 
resolving the uncertainty about the role of these medications with respect to 
reducing cardiovascular risk in everyday clinical practice. .  
 
Cell and Vascular Biology 
Expression of PPARγ, initially thought to be restricted to adipose tissue and effects 
on lipid and carbohydrate metabolism, is now known to be highly expressed in all 
major cell types participating in vascular injury, including endothelial cells, 
macrophages, inflammation and vascular smooth muscle cells (VSMS). As already 
mentioned, TZDs inhibit inflammation  and vascular smooth cell proliferation  by 
decreasing inflammatory cytokine expression, inhibiting endothelial expression of 
adhesion molecules, normalising cell growth, inhibiting migration of VSMCs, 
decreasing hypertension and improving endothelial dysfunction [55]. Other anti-
inflammatory actions may result from the effects of  TZD in decreasing  various 
pro-inflammatory chemokines, such as  C-reactive protein, MMP9, PAI-1 and 
sCD40 in obese and T2DM patients [56], TNF-α, IL-6, and IL-8 in synoviocyte in 
rheumatoid arthritis patients [56]. Reduction in circulating mononuclear cells, 
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nuclear NF-kB content and increase in the same cells the expression of IkB, an 
NK-kB inhibitor have also been shown . Pioglitazone reduces mRNA levels of 
MCP-1 and intercellular adhesion molecule-1 as well as the number of infiltrating 
macrophages in ischaemic cardiac tissue in a rat [57] experimental model. These 
effects suggest that the anti-inflammatory effects of TZDs are likely, at least to 
some extent, to be independent of their insulin sensitising effects [57]. 
Angiotensin (Ang) II plays a major role in hypertension, vascular remodelling and 
insulin resistance. Ang II–induced hypertensive rats exhibit abnormal vascular 
structure. Rosiglitazone treatment in Ang II–infused rats differentially modulates 
PI3K and MAPK signalling in a conduit vessel, aorta, and in mesenteric vessels 
[58]. Rosiglitazone reverses negative changes in the aorta of an Ang II infused rat, 
including Ang II induced elevated blood pressure and intracellular signalling in 
aorta and mesenteric vessels [59].  
 
Renal Effects 
Thiazolidinediones have been shown to have protective effects on the kidney. The 
antiproteinuric effects of the TZDs have been demonstrated in genetically obese 
diabetic rodents [60] and patients with type 2 diabetes and diabetic nephropathy 
[61-62].. In animal models ROS treatment improved renal function and 
histopathology, decreasing pro-inflammatory and pro-fibrotic molecules such as 
AngII, OPN and TGF-beta1 and apoptotic cell death  [60,63],  while in diabetic 
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patients with hypertension and patients with diabetic nephropathy, TZDs have 
been shown to have hemodynamic and antihypertensive effects suggesting that 
the favourable renal effect of PPARγ ligants is probably due to the improved 
glucose metabolism and insulin resistance [64]  and might be independent of their 
capacity to improve glucose tolerance [65]. In addition, results showing the efficacy 
of PPAR-gamma agonists to ameliorate the progression of glomerulosclerosis [60, 
65] suggest that TZDs may provide a novel intervention strategy to prevent 
vascular and glomerular sclerosis. 
 
 
Rosiglitazone in Postmenopausal Diabetic Women 
We have recently demonstrated the effectiveness of rosiglitazone in improving 
vascular function in postmenopausal women with T2DM. We examined the effects 
of rosiglitazone 4mg/day for 12 weeks on glycaemic control, blood pressure and 
compliance of large proximal arteries, as measured by distensibility index (DI). 
Distensibility index is an accessible and reproducible measure of arterial elasticity 
which provides an estimate of the underlying mechanical properties of large 
arteries independent of vessel size [66]. This property may be a modifiable target 
for treatments aiming to reduce cardiovascular disease risk factors associated with 
diabetes and menopause. We found that rosiglitazone improved glycaemic control, 
reduced blood pressure and increased compliance of large proximal arteries. The 
changes induced in the last two variables appeared to be independent of the 
improvements in blood glucose levels [45]. We concluded that that these actions of 
rosiglitazone offer important therapeutic potential for the improvement of 
endothelium dependent and independent function, blood pressure and arterial 
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compliance and maybe reduction of the risk of cardiovascular disease in 
postmenopausal women with type 2 diabetes.  
 
 
Adverse Effects of Thiazolidinediones  
As mentioned, the original member of the TZD class troglitazone was withdrawn 
from use as a result of its association in rare cases with serious liver injury. 
Furthermore, troglitazone failed to increase insulin sensitivity in nondiabetic 
Hispanic women with previous gestational diabetes treated in the Troglitazone in 
Prevention of Diabetes (TRIPOD) study [67].  Although some case reports of liver 
injury inconclusively attributed to ROS and PIO have been reported in the literature 
over the years [68] it is now widely agreed that serious adverse hepatic events with 
ROS and PIO are extremely rare, if they occur at all [69]. Nevertheless, in view of 
the previous experience it is accepted that all TZDs should be avoided in patients 
with liver disease and that regular monitoring should be undertaken of liver 
function tests during the first year of use.  
 
The most common adverse effects associated with thiazolidinedione therapy are 
oedema and weight gain. Both ROS and PIO have been associated with fluid 
retention and peripheral oedema [20, 53, 54], while severe pulmonary oedema has 
been reported to occur more frequently with rosiglitazone use [70,-72], especially 
in elderly patients with congestive heart failure [53, 71] and when combined with 
insulin therapy [73, 74]. To date, the mechanisms underlying these effects have 
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not been fully clarified, although it appears likely that several pathways of action 
are involved [75]. Although spontaneous resolution of oedema has been reported 
with discontinuation of the thiazolidinediones, their use should be avoided in 
patients with congestive heart failure (CHF) or chronic renal insufficiency. TZDs 
have also been associated with increased weight gain in some patients [10, 20, 
28] independently of fluid retention, reflecting increased body fat, although intra-
abdominal fat mass may actually decrease with redistribution to subcutaneous 
tissues [76]. In addition, these agents have been reported to cause anaemia in 
some patients [10], possibly due to haemodilution related to fluid retention. 
 
It is noted that recent results from the PROactive study [54] have shown that 
pioglitazone significantly reduces the composite of all-cause mortality, non-fatal 
myocardial infarction and stroke in patients with T2DM who are at high risk of 
macrovascular events. It showed that PIO is beneficial in patients with T2DM and 
pre-existing macrovascular disease who do not develop heart failure. Nonetheless, 
concern about the possible role of TZDs in worsening congestive heart failure has 
been expressed. Several case reports of acute congestive heart failure have been 
documented [54, 71, 74]. Accordingly, ROS and PIO should not be used in 
patients with acute heart failure [53, 74] and should be discontinued if heart failure 
develops.  
 
New agents may present a more favourable spectrum of action. However, the new 
α/γ TZD, muroglitazar, despite producing greater improvements in glycemic control 
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and lipid profiles [77], has been associated with increased mortality, due either to 
cardiovascular or to cerebrovascular events [78], as a result of which the approval 
of this agent by the U.S. Food and Drug Administration has been deferred until the 
results from large clinical trials on the prognosis of heart failure become available. 
At this time, therefore, the use of ROS and PIO in patients with heart disease 
should be undertaken with caution and patients should be advised that there is 
evidence that such medications may lead to the development or exacerbation of 
CHF. 
 
Conclusions 
TZDs are important insulin-sensitizing agents for improving glucose control and 
reducing insulin resistance. In addition, they improve many other cardiovascular 
risk factors that frequently occur in patients with T2DM, such as endothelium 
dependent and independent dysfunction, hypertension, and arterial stiffness. The 
cardiovascular effects on TZDs are summarized in Table 1. 
 
Despite their effectiveness, ROS and PIO are still widely employed as second line 
agents in the treatment of Type 2 diabetes, after metformin and sulphonylureas, 
medications that have been associated over many years with reduction in 
cardiovascular risk. Results from further large clinical studies are needed to 
confirm the use of TZDs in prevention of T2DM and cardiovascular disease and to 
clarify their long-term impact in diabetic patients. 
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 Lipids Glycemic 
control 
Endothelial 
function 
Inflammatory 
markers 
Oedema Renal 
function 
Weight 
Gain 
Arterial 
Stiffness  
ROS LHL↓ 
HDL ↑ 
TG ↓ 
Improved ↑ ↓ ↑ Improved ↑↓ ↓ 
PIO LDL↓↓ 
HDL ↑ 
TG ↓ 
Improved ↑ ↓ ↑ Improved ↑↓ ↓ 
MUR LDL↓ 
HDL ↑ 
TG ↓ 
Improved N/A N/A ↑ N/A ↑↓ N/A 
 
Table 1. Cardiovascular effects of TZDs 
Legend: ↑= Increased, ↓=Decreased,↔ =No change,↑↓ =Increased/Decreased, N/A= Not 
applicable 
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